Searched for
MANKIND PHARMA FUNDRAISE
Torrent Pharma eyes Rs 12,500-crore bond sale next week. Check detailsNext week, Torrent Pharmaceuticals is set to launch a hefty debt sale, targeting around ₹12,500 crore in fundraising. This capital will pla...- Fund X represents a 60% increase over previous $1.35 billion Fund IX closed in 2022In a landmark move, ChrysCapital has successfully garnered a staggering $2.2 billion for its latest venture, ChrysCapital X, marking a pivo...
- Ranjan Pai, Cipla family eye stake in Zepto; startup moves NCLT to shift domicileZepto’s latest fundraise from local family offices and high-net-worth individuals (HNIs) for up to $150 million – first reported by ET on O...
- Mankind Pharma shares in focus as company approves Rs 10,000 crore fundraise planThe company's board of directors on Monday approved raising up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with...
- Mankind Pharma to raise Rs 10,000 crore through NCDs, CPs to fund BSV dealThe company will raise up to Rs 5,000 crore through non-convertible debentures (NCDs) maturing in up to 48 months, according to a regulator...
- Mankind Pharma board approves raising Rs 10,000 crore through NCDsThe board has established a fundraising committee and granted them the authority to manage all aspects of raising funds, such as deciding t...
- Mankind Pharma eyes ₹9,000 cr via debt to stitch BSV dealThe average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three...
- Oyo parent raises Rs 1,457 crore in latest funding roundOravel Stays Ltd, the parent company of OYO, secured Rs 1,457 crore from several investors, including InCred Wealth, J&A Partners, and ASK ...
- Mankind Pharma taps Barclays and Deutsche Bank for Rs 13,630 cr acquisition of Bharat Serums & VaccinesMankind Pharma has appointed Barclays and Deutsche Bank to arrange financing for its Rs 13,630 crore acquisition of Bharat Serums & Vaccine...
- Mankind to use debt, internal accruals to fund BSV buyoutMankind Pharma announced a ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix o...
- Rs 1.5 lakh crore bid! Retail investors bet on IPOs like never before in 2023In value terms, retail investors applied for shares worth a staggering Rs 1.49 lakh crore, which was a whopping 203% higher than the total ...
- Stocks in news: Infosys, Mankind Pharma, SpiceJet, DLF, DixonInfosys on Monday said its CFO Nilanjan Roy has resigned from the company to pursue other personal aspirations. Nilanjan will continue to b...
- Mankind Pharma's success boosts hopes of more consumer IPOs in IndiaThe strong performance of Mankind Pharma Ltd. in the stock market is expected to lead to more consumer-related initial public offerings (IP...
- Taking Stock: IPO mart sees disappointing H1 as listing gains elude investors. What's in store ahead?The primary market in India has experienced a weak first half with only eight companies launching IPOs, leading to earnings of Rs 5,800 cro...
- IPO activity to pick up pace in 2nd half of 2023: ReportThe IPO market in India has remained steady during Q1 of 2023, with four IPOs taking place during the quarter, one higher than in the same ...
- IPO drought to end in March with nine companies seeking to raise over Rs 17,000 croreJanuary and February did not see any public issues. The high-profile ₹20,000-crore follow-on public offering of Adani Enterprises was calle...
- Multiples Alternate buys into BDR Pharma, invests Rs 750 crET was the first to report in July last year that global and domestic PE funds were in initial discussions to purchase a minority stake in ...
- Pet foods startup Dogsee Chew raises Rs 50 crore in Series A roundDogsee Chew said it will use the funds for brand building, R&D, and building a strong distribution network.
- ChrysCapital unveils $850m new fund, largest till dateThe fund size could go up to $950 million with the firm’s four partners also planning to contribute $50-100 million, the people added.
- ChrysCapital in talks with private equity firms to sell 11% in Mankind Pharma$200 million for its 11% holding, which if realized, with fetch a return of more than 8 times on the seven-year-old investment.
Load More
